Kate Knibbs

While big platforms like Reddit have signed deals with the AI giants, YouTube leaves licensing in the hands of individual creators. The “License to Scrape” program aims to give those streaming stars proper leverage.

OpenAI’s spree of licensing agreements is paying off already—at least in terms of getting publishers to lower their guard.

Mounjaro and Zepbound are now out of shortage. This should be good news—but because so many patients are taking compounded versions of these GLP-1 medications, it's a complicated situation.

photo of A Major GLP-1 Drug Shortage Is Over. Some Patients Aren’t Celebrating image Mounjaro and Zepbound are now out of shortage. This should be good news—but because so many patients are taking compounded versions of these GLP-1 medications, it’s a complicated situation.

photo of A Lawsuit Against Perplexity Calls Out Fake News Hallucinations image In a new copyright lawsuit against AI startup Perplexity, Dow Jones and the New York Post argue that hallucinating fake news and attributing it to real papers is illegal.

photo of The Maker of Ozempic Is Trying to Block Compounded Versions of Its Blockbuster Drug image Novo Nordisk has asked the FDA to block production of compounded copies of Ozempic, arguing that it’s too difficult to do safely. It’s the latest escalation in a brewing war between pharmaceutical companies and compounders.

Novo Nordisk has asked the FDA to block production of compounded copies of Ozempic, arguing that it's too difficult to do safely. It's the latest escalation in a brewing war between pharmaceutical companies and compounders.

The blogging platform Medium is facing an influx of AI-generated content. CEO Tony Stubblebine says it “doesn't matter” as long as nobody reads it.

On’s robot created its new Cloudboom Strike LS performance shoes on-site in three minutes.

An SEO agency owner says he is “very depressed” after one of his AI-assisted Halloween parade listings misled revelers in Dublin, Ireland.